Premium
A PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTORMODIFIED T CELLS DIRECTED AGAINST CD19 IN PATIENTS WITH RELAPSED OR REFRACTORYCD19(+) B CELL LYMPHOMAS: INTERIM ANALYSIS
Author(s) -
Ying Z.,
Xiang X.,
Song Y.,
Ding N.,
Lin Y.,
Zheng W.,
Wang X.,
Lin N.,
Tu M.,
Xie Y.,
Zhang C.,
Liu W.,
Deng L.,
Liu Y.,
Yue Y.,
Yu X.,
Liu H.,
Duan P.,
Chen F.,
Wu X.,
Huang X.F.,
Jones L.,
Kang X.,
Chen S.,
Zhu J.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_131
Subject(s) - medicine , fludarabine , chimeric antigen receptor , follicular lymphoma , lymphoma , cyclophosphamide , gastroenterology , phases of clinical research , diffuse large b cell lymphoma , regimen , interim analysis , oncology , immunology , chemotherapy , immunotherapy , clinical trial , cancer